Radiopharm Theranostics Limited - Special Call

Group 1 - The webinar series is hosted by Radiopharm, featuring discussions on advancements in prostate cancer treatment [1][2] - Dr. Oliver Sartor provided an overview of the prostate cancer treatment landscape, highlighting unmet medical needs and emerging therapies, including the combination of radium-223 with enzalutamide and targeted approaches like PSMA radiotherapeutics [2] - Pluvicto has significantly changed the prostate cancer treatment landscape, demonstrating efficacy in patients before and after chemotherapy, as evidenced by the PSMA 4 and VISION trials, and recently in hormone-sensitive prostate cancer through the PSMAddition trial [3] Group 2 - Despite advancements with PSMA-targeting treatments like Pluvicto, there remains a substantial medical need for new therapies as all patients receiving these treatments will eventually relapse [4]